CORE

🇺🇦   make metadata, not war

    3 research outputs found

    Phase 1 study of CD19 targeted 4-1BBL costimulatory agonist to enhance T cell (glofitamab combination) or NK cell effector function (obinutuzumab combination) in relapsed/refractory B cell lymphoma

    Author
    Publication venue
    'American Society of Hematology'
    Publication date
    Field of study
    No full text
    Ghent University Academic Bibliography

    Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects

    Author
    Publication venue
    'Informa UK Limited'
    Publication date
    Field of study
    No full text
    Crossref

    CD19 4-1BBL (RO7227166) a novel costimulatory bispecific antibody can be safely combined with the T-Cell engaging bispecific antibody glofitamab in relapsed or refractory B-cell Non-Hodgkin lymphoma

    Author
    Publication venue
    Amer Soc Hematology
    Publication date
    Field of study
    No full text
    Ghent University Academic Bibliography
    corecore